OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hamilton on the Complex Treatment Algorithm for HER2+ Breast Cancer

September 8th 2020

Erika P. Hamilton, MD, discusses the complex treatment algorithm for HER2-positive breast cancer.

Dr. Richard on the Benefit of Adding Daratumumab to Standard-of-Care Rd in Myeloma

September 8th 2020

Shambavi Richard, MD, discusses the benefit of adding daratumumab to lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Dr. Chari on the FDA Approval of Belantamab Mafodotin in R/R Multiple Myeloma

September 8th 2020

Ajai Chari, MD, discusses the approval of belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.

Dr. Pautier on the Rationale for the LMS-02 Trial in Soft Tissue Sarcoma

September 8th 2020

Patricia Pautier, MD, discusses the rationale for the phase 2 LMS-02 trial in uterine and soft tissue leiomyosarcoma.

Dr. Mehta on the Current Treatment Paradigm in HER2-Positive Gastric Cancer

September 8th 2020

Rutika J. Mehta, MD, MPH, discusses the current treatment paradigm in HER2-positive gastric cancer.

Dr. Konduri on Sequencing Challenges in ALK+ NSCLC

September 8th 2020

Kartik Konduri, MD, discusses remaining sequencing challenges in ALK-positive non–small cell lung cancer.

Dr. McGregor on the Need to Develop Novel Targets in RCC

September 8th 2020

Bradley McGregor, MD, discusses the need to develop novel, actionable targets in renal cell carcinoma.

Dr. Morris on the Design of the COBRA Trial in Stage II Colon Cancer

September 8th 2020

Van K. Morris, MD, discusses the design of the prospective phase 2/3 NRG-GI005 (COBRA) trial evaluating circulating tumor DNA as a predictive biomarker for adjuvant chemotherapy in patients with colon cancer.

Dr. Subbiah on the FDA Approval of Pralsetinib in RET+ NSCLC

September 5th 2020

Vivek Subbiah, MD, discusses the clinical implications of the approval of pralsetinib in patients with RET fusion–positive non–small cell lung cancer.

Dr. O’Malley on the Safety Profile of Mirvetuximab in Ovarian Cancer

September 3rd 2020

David O'Malley, MD, discusses the adverse effects associated with mirvetuximab soravtansine in ovarian cancer.

Dr. Blank on the OpACIN, OpACIN-neo Trials in Stage III Macroscopic Melanoma

September 3rd 2020

Christian U. Blank, MD, PhD, discusses the OpACIN and OPACIN-neo trials examining ipilimumab plus nivolumab in stage III macroscopic melanoma.

Dr. Shah on Early Benefit of Orvacabtagene Autoleucel in Relapsed/Refractory Myeloma

September 3rd 2020

Nina Shah, MD, discusses the phase 1/2 EVOLVE study with orvacabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr. Leslie on Emerging Therapies in MCL

September 3rd 2020

Lori A. Leslie, MD, lymphoma attending, discusses emerging therapies in mantle cell lymphoma.

Dr. Rizvi on the Utility of Trastuzumab Deruxtecan in NSCLC

September 3rd 2020

Naiyer A. Rizvi, MD, discusses the utility of fam-trastuzumab deruxtecan-nxki in non–small cell lung cancer.

Dr. Pennell on Remaining Challenges in NSCLC

September 3rd 2020

Nathan A. Pennell, MD, PhD, discusses remaining challenges in non–small cell lung cancer.

Dr. Halfdanarson on Investigational Agents in Driver-Negative CRC

September 3rd 2020

Thorvardur (Thor) Halfdanarson, MD, discusses investigational agents that are being evaluated in patients with colorectal cancer who do not harbor genomic alterations.

Dr. Ahmed on the Impact of Neratinib on CNS Metastases in HER2+ Breast Cancer

September 3rd 2020

Kamran A. Ahmed, MD, discusses the impact of neratinib on patients with central nervous system metastases and HER2-positive breast cancer.

Dr. Vaishampayan on the Need to Develop Novel Therapies in mRCC

September 3rd 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the need to develop novel therapies for patients with metastatic renal cell carcinoma.

Dr. Jacobson on the ZUMA-5 Trial With Axi-Cel in High-Risk Relapsed/Refractory iNHL

September 2nd 2020

Caron Jacobson, MD, discusses the high-risk patient population within relapsed/refractory indolent non-Hodgkin lymphoma included in the phase 2 ZUMA-5 study.

Dr. Motzer on the TIVO-3 Trial Examining Tivozanib in Advanced RCC

September 2nd 2020

Robert J. Motzer, MD, discusses the results of the phase 3 TIVO-3 trial with tivozanib versus sorafenib in patients with advanced renal cell carcinoma.